Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

07:12
10/06/16
10/06
07:12
10/06/16
07:12

Alnylam setback has no read-through to Medicines Co., says Jefferies

Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 14

    Oct

  • 06

    Nov

MDCO The Medicines Co.
$38.51

0.32 (0.84%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views today's selloff in shares of Alnylam Pharmaceuticals after the company discontinued its revusiran program as a buying opportunity. The analyst does not believe the discontinuation has read-through to the Phase III APOLLO trial or seven other RNAi drugs that employ ESC-GalNAc technology. He lowered his price target for Alnylam shares to $106 from $118 and keeps an Overweight rating on the name. JPMorgan and Barclays this morning downgraded the shares.
10/06/16
JPMS
10/06/16
DOWNGRADE
Target $51
JPMS
Neutral
Alnylam downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Alnylam Pharmaceuticals to Neutral after the company said it will discontinue Revusiran for the treatment of Familial Amyloid Cardiomyopathy. The analyst viewed the drug as a "key asset" and cut his price target for the shares to $51 from $83. Barclays this morning also downgraded Alnylam.

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$72.39

1.08 (1.51%)

, KR

Kroger

$33.29

0.3 (0.91%)

06:06
02/27/17
02/27
06:06
02/27/17
06:06
Periodicals
Wal-Mart launching price-comparison test in U.S., targeting Aldi, Reuters says »

Wal-Mart (WMT) is…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

KR

Kroger

$33.29

0.3 (0.91%)

PG

Procter & Gamble

$91.05

-0.08 (-0.09%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

CAG

Conagra Brands

$41.16

0.66 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

LJPC

La Jolla

$19.87

1.65 (9.06%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Hot Stocks
La Jolla announces positive results from ATHOS-3 Phase 3 study of LJPC-501 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$45.61

1.36 (3.07%)

06:04
02/27/17
02/27
06:04
02/27/17
06:04
Downgrade
PSEG rating change  »

PSEG downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Hot Stocks
Breaking Hot Stocks news story on UCP, Inc. »

UCP, Inc. reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LAUR

Laureate Education

$13.24

0.06 (0.46%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:02
02/27/17
02/27
06:02
02/27/17
06:02
Earnings
UCP, Inc. reports Q4 EPS 89c with benefits, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNAP

Snap Inc.

06:01
02/27/17
02/27
06:01
02/27/17
06:01
Periodicals
Snap founders tightened grip following dispute with Lightspeed, NYT reports »

Early Snap investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

GRAM

Grana y Montero

$3.32

-1.77 (-34.77%)

06:00
02/27/17
02/27
06:00
02/27/17
06:00
Downgrade
Grana y Montero rating change  »

Grana y Montero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

05:59
02/27/17
02/27
05:59
02/27/17
05:59
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.66

0.13 (0.10%)

, EBAY

eBay

$34.06

0.46 (1.37%)

05:58
02/27/17
02/27
05:58
02/27/17
05:58
Periodicals
Tech firms plan to file brief in favor of transgender rights, Axios reports »

Leading tech companies…

AAPL

Apple

$136.66

0.13 (0.10%)

EBAY

eBay

$34.06

0.46 (1.37%)

IBM

IBM

$181.35

-0.3 (-0.17%)

MSFT

Microsoft

PYPL

PayPal

$43.07

0.54 (1.27%)

CRM

Salesforce

$81.78

-0.29 (-0.35%)

YELP

Yelp

$33.46

-0.01 (-0.03%)

BOX

Box

$17.93

0.41 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 09

    May

AFL

Aflac

$71.71

-0.01 (-0.01%)

05:57
02/27/17
02/27
05:57
02/27/17
05:57
Upgrade
Aflac rating change  »

Aflac upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

FTI

TechnipFMC

$32.30

-0.58 (-1.76%)

05:56
02/27/17
02/27
05:56
02/27/17
05:56
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$57.00

2.32 (4.24%)

, ISIL

Intersil

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$57.00

2.32 (4.24%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

ENB

Enbridge

$41.34

-0.37 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

NCMI

National CineMedia

$12.08

-0.35 (-2.82%)

05:53
02/27/17
02/27
05:53
02/27/17
05:53
Recommendations
National CineMedia analyst commentary  »

National CineMedia added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

HMSY

HMS Holdings

$18.83

0.13 (0.70%)

05:48
02/27/17
02/27
05:48
02/27/17
05:48
Downgrade
HMS Holdings rating change  »

HMS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

TEX

Terex

$30.35

0.44 (1.47%)

05:45
02/27/17
02/27
05:45
02/27/17
05:45
Upgrade
Terex rating change  »

Terex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

TPH

TRI Pointe

$12.21

0.1 (0.83%)

05:43
02/27/17
02/27
05:43
02/27/17
05:43
Downgrade
TRI Pointe rating change  »

TRI Pointe downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

05:39
02/27/17
02/27
05:39
02/27/17
05:39
Recommendations
J.C. Penney analyst commentary  »

J.C. Penney price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SUI

Sun Communities

$83.52

1.2 (1.46%)

05:37
02/27/17
02/27
05:37
02/27/17
05:37
Downgrade
Sun Communities rating change  »

Sun Communities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

AVGO

Broadcom

$210.37

-0.21 (-0.10%)

05:34
02/27/17
02/27
05:34
02/27/17
05:34
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 16

    Mar

LAUR

Laureate Education

$13.24

0.06 (0.46%)

05:32
02/27/17
02/27
05:32
02/27/17
05:32
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$257.00

1.01 (0.39%)

05:31
02/27/17
02/27
05:31
02/27/17
05:31
Downgrade
Tesla downgraded to Sell from Neutral at Goldman »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRDXF

Nordex

$14.35

-5.1 (-26.22%)

05:26
02/27/17
02/27
05:26
02/27/17
05:26
Downgrade
Nordex rating change  »

Nordex downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.